RxDoctor Payments Data

Nazish Ekram, MD

Internal Medicine · Naperville, ILNPI 1346496965

Payments from drug & device makers

$15,178in general payments, 2019–2025

Across 415 payments — averaging $36.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$6K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AbbVie$2K
  • Bayer$797
  • Currax Pharmaceuticals LLC$589
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$4,35029%
  • Travel & lodging$8916%
  • Food & beverage$9,82065%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,178 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$53,132
Medicare patients
95
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$216,257
MounjaroTirzepatide103$128,685
WegovySemaglutide36$47,428
FarxigaDapagliflozin Propanediol36$41,369
RybelsusSemaglutide20$38,115
JardianceEmpagliflozin23$29,887
KerendiaFinerenone12$13,105
ContraveNaltrexone Hcl/Bupropion Hcl13$11,830
VascepaIcosapent Ethyl20$6,552
Naltrexone Hcl53$2,854
Metformin Hcl ErMetformin Hcl161$1,592
Topiramate113$998
Duloxetine Hcl12$556
Doxepin Hcl25$325
Levothyroxine Sodium12$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$2,422$301,801184 claims
Lilly USA, LLCMounjaro$1,822$128,685103 claims
AstraZenecaFarxiga$430$41,36936 claims
Boehringer IngelheimJardiance$5,734$29,88723 claims
BayerKerendia$797$13,10512 claims
Currax Pharmaceuticals LLCContrave$589$11,83013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →